



APR 08 2002 FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/536-5201
FACSIMILE: 512/536-5202

WRITER'S INTERNET ADDRESS:
PSUBRAMONY@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3067

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

0430
#2

April 3, 2002

FILE: UTSD:771US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 3, 2002
Date

Priya Subramony
Priya D. Subramony

Commissioner for Patents
Washington, DC 20231

RE: SN 10/074,220 "DIAGNOSIS AND TREATMENT OF INFLAMMATION AND HYPERACTIVE IMMUNE CONDITIONS" - Tadashi Kumamoto et al. (Client Reference: UTSD:0771)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C32).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201672/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Priya Subramony

Priya D. Subramony
Patent Agent
Reg. No. 50,939

PDS/cmb
Encl: as noted



PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Tadashi Kumamoto *et al.*

Serial No.: 10/074,220

Filed: February 12, 2002

For: DIAGNOSIS AND TREATMENT OF
INFLAMMATION AND HYPERACTIVE
IMMUNE CONDITIONS

Group Art Unit: Unknown


Examiner: Unknown

Atty. Dkt. No.: UTSD:771US/SLH

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 3, 2002
Date


Priya D. Subramony

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201672/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 3, 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:771US/SLH Serial No.
10/074,220

U.S. Patent & Trademark Office
APR 8 2002 INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant
Tadashi Kumamoto *et al.*Filing Date:
February 12, 2002Group:
UnknownU.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1***U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Berchtold <i>et al.</i> , "Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases," <i>FEBS Lett.</i> , 458:424-428, 1999.
	C2	Betto, <i>et al.</i> , "Ecto-ATPase activity of alpha-sarcoglycan (adhalin)" <i>J. Biol. Chem.</i> , 274: 7907-7912, 1999.
	C3	Biederbick, <i>et al.</i> , "A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles," <i>J. Cell Sci.</i> , 112: 2473-2484, 1999.
	C4	Chadwick and Frischauf, "The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from <i>Drosophila melanogaster</i> ," <i>Genomics</i> , 50:357-367, 1998.
	C5	Coutinho-Silva <i>et al.</i> , "P2Z/P2X7 receptor-dependent apoptosis of dendritic cells," <i>Am. J. Physiol.</i> , 276:C1139-C1147, 1999.
	C6	Di Virgilio, <i>et al.</i> , "Nucleotide receptors: an emerging family of regulatory molecules in blood cells," <i>Blood</i> , 97: 587-600, 2001.
	C7	Dumbrowski <i>et al.</i> , "Ecto-ATPase: an activation marker necessary for effector cell function," <i>Immunol Rev.</i> , 161:111-118, 1998.
	C8	Effendy, <i>et al.</i> , "Epidermal cytokines in murine cutaneous irritant responses," <i>J. Appl. Toxicol.</i> , 20: 335-341, 2000.

25144084.1

DATE CONSIDERED:**EXAMINER:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

list of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Atty. Docket No.
UTSD:771US/SLH

Serial No.
10/074,220

Applicant
Tadashi Kumamoto *et al.*

Filing Date:
February 12, 2002

Group:
Unknown

U.S. Patent Documents
See Page 1

Foreign Patent Documents
See Page 1

Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
C9		Enjyoji, <i>et al.</i> , "Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation," <i>Nat. Med.</i> , 5:1010-1017, 1999.
C10		Ferrari, <i>et al.</i> , "The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release," <i>FASEB J.</i> , 14: 2466-2476, 2000.
C11		Filippini, <i>et al.</i> , "Extracellular ATP in T-lymphocyte activation: possible role in effector functions," <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 87: 8267-8271, 1990.
C12		Girolomoni <i>et al.</i> , "Epidermal Langerhans cells are resistant to the permeabilizing effects of extracellular ATP: in vitro evidence supporting a protective role of membrane ATPase," <i>J. Invest Dermatol.</i> , 100:282-287, 1993.
C13		Heine, <i>et al.</i> , "Functional characterization of rat ecto-ATPase and ecto-ATP diphosphohydrolase after heterologous expression in CHO cells," <i>Eur J Biochem.</i> , 262(1):102-107, 1999.
C14		Imai, <i>et al.</i> , "CD39 modulates IL-1 release from activated endothelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 270: 272-278, 2000.
C15		Knowles and Nagy, "Inhibition of an ecto-ATP-diphosphohydrolase by azide," <i>Eur. J. Biochem.</i> , 262:349-357, 1999.
C16		Liu <i>et al.</i> , "Expression and a role of functionally coupled P2Y receptors in human dendritic cells," <i>FEBS Lett.</i> , 445:402-408, 1999.
C17		Marriott, <i>et al.</i> , "Extracellular uridine nucleotides initiate cytokine production by murine dendrite cells," <i>Cell. Immunol.</i> , 195:147-156, 1999.
C18		Matsue <i>et al.</i> , "Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells," <i>Nature Med.</i> , 5:930-937, 1999.
C19		Matsue, <i>et al.</i> , "Keratinocyte-derived IL-7 serves as a growth factor for dendritic epidermal T-cells in mice," <i>J. Immunol.</i> , 151:6012-6019, 1993.
C20		Mummert, <i>et al.</i> , "Development of a peptide inhibitor or hyaluronan-mediated leukocyte trafficking," <i>J. Exp. Med.</i> , 192:769-779, 2000.
C21		Mutini <i>et al.</i> , "Mouse dendritic cells express the P2X ₆ purinergic receptor: characterization and possible participation in antigen presentation," <i>J. Immunol.</i> , 163:1958-1965, 1999.

25144084.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:771US/SLHSerial No.
10/074,220

CIP E
APR 08 2002
PATENT & TRADEMARK OFFICE
List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant
Tadashi Kumamoto *et al.*Filing Date:
February 12, 2002Group:
UnknownU.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C22	Nihei, <i>et al.</i> , "Pharmacologic properties of P _{2U} /P _{2X₇} receptor characterized in murine dendritic cells: role on the induction of apoptosis," <i>Blood</i> , 96: 996-1005, 2000.
	C23	Ralevic and Burnstock, "Receptors for purines and pyrimidines," <i>Pharmacol. Rev.</i> 50:413-492, 1998.
	C24	Sellers, <i>et al.</i> , "Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis," <i>J. Biol. Chem.</i> , 276: 16379-16390, 2001.
	C25	Sevigny, <i>et al.</i> , "Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase," <i>J. Biol. Chem.</i> , 275: 5640-5647, 2000.
	C26	Wang, and Guidotti, "Golgi localization and functional expression of human uridine diphosphatase," <i>J. Biol. Chem.</i> , 273: 11392-11399, 1998.
	C27	Warny, <i>et al.</i> , "P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide," <i>J. Biol. Chem.</i> , 276: 26051-26056, 2001.
	C28	Williams and Jarvis, "Purinergic and pyrimidinergic receptors as potential drug targets," <i>Biochem. Pharmacol.</i> , 59:1173-1185, 2000.
	C29	Xu, <i>et al.</i> , "Successive generation of antigen-presenting, dendritic cell lines from murine epidermis," <i>J. Immunol.</i> , 154:2697-2705, 1995.
	C30	Zhong and Guidotti, "A yeast Golgi E-type ATPase with an unusual membrane topology," <i>J. Biol. Chem.</i> , 274:32704-32711, 1999.
	C31	Ziganshina, <i>et al.</i> , "Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved," <i>Inflamm. Res.</i> , 45: 96-102, 1996.
	C32	Zinchuk <i>et al.</i> , "Ecto-ATPase activity in cerebellum: implication to the function of synaptic transmission," <i>Brain Res.</i> 815:111-115, 1999.

25144084.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.